1 / 23

ICCS e-Newsletter CSI Winter 2012

ICCS e-Newsletter CSI Winter 2012. Julia Almeida, MD PhD Department of Medicine and Cancer Research Center University of Salamanca Salamanca, Spain. e-CSI – History and physical examination.

charde-alexander
Download Presentation

ICCS e-Newsletter CSI Winter 2012

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ICCS e-Newsletter CSI Winter 2012 • Julia Almeida, MD PhD • Department of Medicine and Cancer Research Center • University of Salamanca • Salamanca, Spain

  2. e-CSI – History and physical examination • A 77-year-old male with no significant past medical historywas studied because of a lymphocytosis detected in a routine blood analysis • Patient was asymptomatic • Physical examination did not revealed any pathological sign (no organomegalies, no skin involvement)

  3. e-CSI – Peripheral blood cell counts

  4. e-CSI – CBC differential PB: Peripheralblood

  5. e-CSI – Biochemical parameters

  6. e-CSI – Work-up and evaluation • Peripheral Blood in EDTA was received for evaluation of lymphocytosis • Flow cytometricimmunophenotypingwas performed on this sample, and the results from selected multiple-stained tubes are provided for review:

  7. e-CSI – Flow cytometric (FCM) studies Data acquisition was performed in a FACSCanto II (BDB); data analysis was done with the INFINICYT software (Cytognos SL) Sequential FCM strategy and combinations of fluorochromeMAb used: e-Newsletter CSI Summer 2010 cytPERF: cytoplasmicperforine; cytGRZ: cytoplasmicgranzyme B

  8. e-CSI – Flow cytometric (FCM) studies Step 1: screening tube Exclusion of debris Displayonly CD3+ T cells Selection of T cells Refiningselection of T cells CD4+ gated T cells CD3+ gated T cells CD4+ gated T cells CD4+ gated T cells 94% CD56+/CD4+ T cells Most CD4+ T cells (94%) are CD56+. In addition, they show partialexpression of CD8dim and higher SSC values in comparisonto CD56- CD4+ T cells Thesecellsrepresentaround 67% of total leukocytes 94% CD4+ T cells (CD4/CD8 ratio: 15.5)

  9. e-CSI – Flow cytometric (FCM) studies Step 1: screening tube Conclusion The lymphocytosis is at expense of CD4+ T cells showing cytotoxic-related markers: expression of CD56, partial expression of CD8dim and high SSC values (67% of all WBC; 9.78 x 109 cells/l) Are these expanded cells clonal?

  10. e-CSI – Flow cytometric (FCM) studies Step 2: assessment of T-cell clonality CD3+ livegate Displayonly CD3+ T cells CD3+ livegate Selection of T cells Refiningselection of T cells CD3+ gated T cells CD4+ gated T cells Selection of CD4+ T cells Around 93% of CD4+ T cells expressthesame TCR-Vbetaregion (TCR-Vb13.1+) Thisspecifictube has beenselectedfromthe total panel of theTCR Vbeta Kit IOTest Beta Mark IM3497, which includes a total of 24 MAb against different TCR-Vb regions in a 8-tube format

  11. e-CSI – Flow cytometric (FCM) studies Step 2: assessment of T-cell clonality Conclusion YES, the expanded CD4+ T-cells are clonal, as they express the same TCR-Vbeta region assessed by FCM (TCR-Vb13.1+)

  12. e-CSI – Flow cytometric (FCM) studies Step 3: phenotypic characterization After applying the same gating strategy as previously shown to identify CD4+ T cells, then we proceed to characterize them: Normal residual CD4+ T cells Clonal CD4+ T cells Clonal CD4+ T cells are mostly CD7-, CD26- and CD28- and CD2hi

  13. e-CSI – Flow cytometric (FCM) studies Step 3: phenotypic characterization After applying the same gating strategy as previously shown to identify CD4+ T cells, then we proceed to characterize them: Clonal CD4+ T cells Normal residual CD4+ T cells Clonal CD4+ T cells show a typicalphenotype of effectorcells: CD45RA+ / CD197 (CCR7)- / CD27- / CD45RO-/+dim

  14. e-CSI – Flow cytometric (FCM) studies Step 3: phenotypic characterization After applying the same gating strategy as previously shown to identify CD4+ T cells, then we proceed to characterize them: Clonal CD4+ T cells Normal residual CD4+ T cells Clonal CD4+ T cells are CD5+, CD8-/dim , cytTCL1- and HLADR+heterogeneous

  15. e-CSI – Flow cytometric (FCM) studies Step 3: phenotypic characterization After applying the same gating strategy as previously shown to identify CD4+ T cells, then we proceed to characterize them: Clonal CD4+ T cells Normal residual (+someclonal) CD4+ T cells 85% of total CD4+ T cells are CD57+. All CD4+ T cells are CD11c- and CD30-

  16. e-CSI – Flow cytometric (FCM) studies Step 3: phenotypic characterization After applying the same gating strategy as previously shown to identify CD4+ T cells, then we proceed to characterize them: Clonal CD4+ T cells Normal residual CD4+ T cells Clonal CD4+ T cellsexpressPerforine and Granzyme B at thecytoplasmiclevel and are mostly CD94- and CD16-

  17. Large Granular Lymphocytosis / Leukemia Large granular lymphocyte (LGL) leukemia is a well-recognized disorder of clonal mature CD8+ T lymphocytes or less frequently natural killer cells; in addition, it has recently been shown that clonal LGL lymphocytosis / leukemia may also derive from CD4+ LGL T cells

  18. TCRab+/CD4+ Large Granular Lymphocytosis / Leukemia Clinical characteristics • These cases usually display an indolent clinical course –although rare cases associated with aggressive disease have also been reported – associated with a significantly lower frequency of cytopeniasthan CD8+ LGL leukemias • Accordingly, diagnosis is usually made from a lymphocytosisdetected in a routine blood analysis (>80%) • However, these patients frequently (30%) show associated neoplasias(particularly B-cell chronic leukemias/lymphomas), so clinical outcome is determined by the associated tumor Lima et al, Am J Pathol 2003

  19. TCRab+/CD4+ Large Granular Lymphocytosis / Leukemia Phenotypic characteristics of clonal cells CD4+/NKa+/CD8-/+dimT cells display relatively high FSC/SSC values and frequentdimreactivityfor CD8, and show a phenotype of activated (CD7-/dim/CD2h/HLADR+) peripheral memory or effector(CD26-/CD27-/CD28-/CCR7- with frequent coexpression of CD45RA and RO) cytotoxic (usually CD57+/CD56+and granzyme B + /perforine + ) T cells in the absence of other Nka markers (i.e. CD16, CD94, CD161) Lima et al, Am J Pathol 2003

  20. TCRab+/CD4+ Large Granular Lymphocytosis / Leukemia 45 40 Normal CD4+ T cells 35 30 Clonal CD4+ LGL T cells 25 20 15 10 5 0 vb1 vb9.1 vb8.1 vb6.7 vb7.1 vb5.2 vb6.1 vb18.1 vb5.1 vb5.3 vb2.1 vb3.1 vb11 vb16.1 vb12.2 vb13.1 vb13.6 vb14.1 vb17.1 vb23.1 vb21.3 vb22.1 vb20 Analysis of the TCR-Vbrepertoirebyimmunophenotype Percentage of cases TCRab+/CD4+ Large Granular Lymphocytosis / Leukemia have a restricted TCR-Vb repertoire with a preferential usage of a few TCR-Vb families; notably, in more than 40% of cases clonal cells are TCR-Vb 13.1+ Lima et al, Am J Pathol 2003

  21. TCRab+/CD4+ Large Granular Lymphocytosis / Leukemia In additiontotherestricted TCR-Vbrepertoire, otherevidencesstronglysupportthefact of theexistence of a commonantigen-drivenorigin • Thereis a clearassociationbetweenthe TCR-Vbrepertoire and the HLA genotype: all TCR-Vb13.1+ cases are HLADR*0701 • HLADR7/TCRVb13.1+cases show a highlyhomogeneous and strikingly similar TCR (highhomologyin theirCDR3) Garrido et al, Blood 2007 ¿Whatisthenature of theantigen? Clonal CD4+ LGL T cells showfunctional response tohCMV Rodriguez-Caballero et al, Blood 2008

  22. TCRab+/CD4+ Large Granular Lymphocytosis / Leukemia Summary Patients with CD4+/NKa+/CD8-/+dim T-LGL lymphocytosis / leukemia show an indolent course of the disease; however, they frequently have a second neoplasiaand clinical outcome is usually determined by the associated tumor Clonal CD4+/NKa+/CD8-/+dim T-cells show a typically activated, cytotoxic phenotype of effector T-LGL cells and a restricted TCR-Vb repertoire, with a preferential usage of a few TCR-Vb families TCR-Vb13.1+ patients display a common HLA-DRB1*0701 genotype and clonal cells express identical motifs in their CDR3-TCR-V sequences, supporting a common antigen-driven origin Clonal T cells usually display response to hCMV, suggesting the potential involvement of hCMV in the ontogeny of CD4+/NKa+/CD8-/+dim T-LGL lymphocytosis / leukemia - - - -

  23. TCRab+/CD4+ Large Granular Lymphocytosis / Leukemia References Lima M, Almeida J, Dos Anjos Teixeira M, et al. TCRalphabeta+/CD4+ large granular lymphocytosis: a new clonal T-celllymphoproliferativedisorder. Am J Pathol. 2003 Aug;163(2):763-71. Garrido P, Ruiz-Cabello F, Bárcena P, et al. Monoclonal TCR-Vbeta13.1+/CD4+/NKa+/CD8-/+dim T-LGL lymphocytosis: evidenceforanantigen-drivenchronic T-cellstimulationorigin.Blood. 2007 Jun 1;109(11):4890-8. Ghia P, Prato G, Stella S, Scielzo C, Geuna M, Caligaris-Cappio F. Age-dependentaccumulation of monoclonal CD4+CD8+ double positive T lymphocytes in theperipheralblood of theelderly. Br J Haematol. 2007 Dec;139(5):780-90. Rodríguez-Caballero A, García-Montero AC, Bárcena P, et al. Expandedcells in monoclonal TCR- alphabeta+/CD4+/NKa+/CD8-/+dim T-LGL lymphocytosisrecognizehCMVantigens.Blood. 2008 Dec 1;112(12):4609-16. Olteanu H, Karandikar NJ, Eshoa C, Kroft SH. Laboratoryfindings in CD4(+) large granular lymphocytoses.Int J LabHematol. 2010 Feb;32(1 Pt 1):e9-16. Sáez-Borderías A, Romo N, Ruiz-Cabello F, et al. Natural killercell receptor expressionreflectsthe role of humancytomegalovirus in thepathogenesis of a subset of CD4+ T-celllarge granular lymphocytosis.HumImmunol. 2011 Mar;72(3):226-8.

More Related